Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07647224
PHASE1

A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and immunogenicity characteristics of GR2301 injection in healthy adult subjects in China. The Multiple doses will be gradually escalated.

Official title: A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity Profiles of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-06

Completion Date

2027-07

Last Updated

2026-06-15

Healthy Volunteers

Yes

Interventions

DRUG

GR2301 injection

IL15 monoclonal antibody

Locations (1)

Beijing Tongren Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China